Drug-drug interactions: is there an optimal way to study them?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.British journal of clinical pharmacology · 2011
   Trial
2. Evaluation of drug-drug interaction potentials between JP-1366 and celecoxib using physiologically based pharmacokinetic modeling.Translational and clinical pharmacology · 2025
   Article
3. Regulation of chronic neuroinflammation through dietary herbal products.Frontiers in nutrition · 2025
   Review
4. A computational approach to predict multi-pathway drug-drug interactions: A case study of irinotecan, a colon cancer medication.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020
   Article
5. An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors.European journal of drug metabolism and pharmacokinetics · 2020
   Article
6. Health Outcome Prioritization in Alzheimer's Disease: Understanding the Ethical Landscape.Journal of Alzheimer's disease : JAD · 2020
   Review
7. Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing.Scientific reports · 2016
   Article
8. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
   Review
9. Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France.European journal of clinical pharmacology · 2013
   Article
10. The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.European journal of clinical pharmacology · 2012
    Article
11. Drug-drug interactions--bridging the gulf between the bench and the bedside?British journal of clinical pharmacology · 2011
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as